A Study of 99mTc-3PRGD2 Injection in Healthy Volunteers
Status:
Completed
Trial end date:
2019-01-18
Target enrollment:
Participant gender:
Summary
The study drug 99mTc-3PRGD2 of this study is a new radioactive diagnostic preparation for
clinical use as a nuclear medicine molecular probe for tumor SPECT/CT imaging.
After 99mTc-3PRGD2 is injected into the body, it is specifically taken up by integrin
receptor-positive tumor tissue, and tumor tissue is developed by SPECT/CT, which can be used
for molecular imaging diagnosis and individualized treatment of common tumors.
The primary objectives of this study is to examine the pharmacokinetics the safety of
99mTc-3PRGD2 injection in healthy volunteers, as well as the biodistribution in the human
body and to estimate the dose of internal radiation absorbed. This study provides the basis
for the design of phase II clinical research programs.